PSMA PET in Prostate Cancer

Jadvar, Hossein

doi:10.2967/jnumed.115.157339

Cited by 41 publications

(24 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The preliminary published results suggest that this radiotracer has high potential for diagnostic utility in prostate cancer, although prospective studies are required to exactly define the performance of 68 Ga-labelled PSMA compared with 11 C-labelled or 18 F-labelled choline for prostate cancer staging and r estaging compared to choline. 65 Besides new innovative radiotracers that could be used to stage and restage prostate cancer, new imaging techno logies could improve the assessment of this disease. Combined PET-MRI is one of the most promising techniques that has been introduced into a few centres and could positively affect the clinical management of patients with prostate cancer.…”

Section: Future Perspectivesmentioning

confidence: 99%

Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT

Mapelli

Picchio

2015

Nat Rev Urol

View full text Add to dashboard Cite

An early and correct diagnosis together with accurate staging of prostate cancer is necessary in order to plan the most appropriate treatment strategy. Morphological imaging modalities such as transrectal ultrasonography (TRUS), CT, and MRI can have some limitations regarding their accuracy for primary diagnosis and staging of prostate cancer; for instance, they have limited specificity in differentiating cancer from benign prostatic conditions and, by using size as the only criterion to characterize lymph node metastases, they might not be accurate enough for tumour characterization. In this scenario, PET-CT with (11)C-labelled or (18)F-labelled choline derivatives provides morphological and functional characterization and could overcome the limitations of the conventional imaging techniques. PET-CT is one of the most investigated molecular imaging modalities for prostate cancer diagnosis and staging. Currently, the main investigations on the role of PET-CT in the diagnosis and staging of prostate cancer have been performed on a retrospective basis and this type of analysis might be one of the main reasons why different results regarding its diagnostic accuracy have been reported.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT

Mapelli

Picchio

2015

Nat Rev Urol

View full text Add to dashboard Cite

show abstract

“…For example, changes in SUV for the sum of all lesions early in treatment do not appear to be associated with outcome, although further analyses of several cohorts are in longer-term follow-up (42). And finally, specific scanning targets such as the androgen receptor, PSMA, bombesin receptors, and other molecules may provide information that could indicate potential for early response prediction and therapeutic change (55,73,(79)(80)(81)91,115). These targets will need to be tested in a series of prospective studies (116)(117)(118).…”

Section: Smentioning

confidence: 99%

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer

Ballas

Abreu

Quinn³

2016

J Nucl Med

View full text Add to dashboard Cite

As molecular imaging better delineates the state of prostate cancer, clinical management will evolve. The currently licensed imaging modalities are limited by lack of specificity or sensitivity for the extent of cancer and for predicting outcome in response to therapy. Clinicians want molecular imaging that-by being more reliable in tailoring treatment and monitoring response for each patient-will become a key facet of precision medicine, surgery, and radiation therapy. Identifying patients who are candidates for specific or novel treatments is important, but equally important is the finding that a given patient may not be a good candidate for single-modality therapy. This article presents prostate cancer scenarios in which managing clinicians would welcome molecular imaging innovations to help with decision making. The potential role of newer techniques that may help fill this wish list is discussed.

show abstract

“…Particularly, the 68Ga-labeled PSMA inhibitor, Glu-NH-CO-NHLys-(Ahx)-[68Ga-HBED-CC], abbreviated as 68Ga-PSMA, has received much attention demonstrating high-diagnostic performance in early human studies. The construct may also be amenable for use in targeted radionuclide therapy with an appropriate particle emitter [62]. …”

Section: Other Emerging Pet Radiotracersmentioning

confidence: 99%

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Jadvar

2016

Abdom Radiol

Self Cite

View full text Add to dashboard Cite

Prostate cancer is a prevalent public health problem worldwide. While imaging has played a major role in this disease, there still remain many challenges and opportunities. Positron emission tomography with various physiologically based radiotracers is fundamentally suited to interrogate this biologically and clinically heterogeneous disease along the course of its natural history. In this article, I review briefly the published evidence for the use of positron emission tomography with 18F-fluorodeoxyglucose, 11C-acetate, and 18F- or 11C-choline in the imaging evaluation of prostate cancer. Although the focus of the article will be on these radiotracers given the accumulated experience with them, but I will also comment on the outlook for the use of other emerging PET radiotracers such as those targeted to the prostate-specific membrane antigen and the amino acid metabolism pathway. It is anticipated that PET will play major role in the evaluation of prostate cancer in the current evidence-based medicine environment. There will also be exciting novel prospects for the use of therapeutic-diagnostic (theransotic) pairs in the management of patients with prostate cancer.

show abstract

PSMA PET in Prostate Cancer

Cited by 41 publications

References 14 publications

Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT

Initial prostate cancer diagnosis and disease staging—the role of choline-PET–CT

What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer

Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer

Contact Info

Product

Resources

About